AROC-3 by Arrowhead Pharmaceuticals for IgA Nephropathy (Berger’s Disease): Likelihood of Approval

AROC-3 is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for IgA Nephropathy (Berger’s Disease).

Personalized dietary programs outperform general advice for better heart health

Study found that personalized dietary programs (PDP) led to significant improvements in cardiometabolic health compared to standard dietary advice, with notable reductions in weight, triglyceride

May 14, 2024

First genetic marker for MS severity discovered

Scientists identify the first genetic marker for MS severity, opening the door to preventing long-term disability.

June 28, 2023

How including young voices in family disputes can transform mediation and court outcomes

Giving children a right to be heard and taken seriously when parents separate could help couples reach sustainable child arrangements and relieve significant backlogs in

August 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.